Search
Apogee Therapeutics' CEO Michael Henderson discusses today's 52 week maintenance data for the company's extended-dose IL-13 inhibitor in atopic dermatitis
He discusses the the data and how he compares it to Dupixent and other medicines on the market, how translatable the data might be to a phase 3 that will be up and running later this year, and what other data the company will have in the near future.
Mar 23
Apogee will have at lest four key trial readouts for its half-life optimized IL-13 program next year, including monotherapy trials and in combination with OX40L and TSLP.
CEO Michael Henderson walks us through what will be a busy year for the company. Coverage brought to you by
Nov 12, 2025
Taking a deep dive into atopic dermatitis with the CEO of Apogee Therapeutics
Michael Henderson describes the rationale behind Apogee's IL13 program and how it has been designed to have a longer half-life.
Dec 7, 2023
.png){kind=logo}
